JP7848190B2 - 生体侵食性眼薬送達挿入物及び治療方法 - Google Patents

生体侵食性眼薬送達挿入物及び治療方法

Info

Publication number
JP7848190B2
JP7848190B2 JP2023515802A JP2023515802A JP7848190B2 JP 7848190 B2 JP7848190 B2 JP 7848190B2 JP 2023515802 A JP2023515802 A JP 2023515802A JP 2023515802 A JP2023515802 A JP 2023515802A JP 7848190 B2 JP7848190 B2 JP 7848190B2
Authority
JP
Japan
Prior art keywords
approximately
eye
pva
day
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541056A (ja
JP2023541056A5 (enExample
Inventor
サイード サイム，
ミシェル ハワード‐スパークス，
ダリオ パッジャリーノ，
バーゼル カルゾウン，
ジャンビン チェン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EyePoint Inc
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of JP2023541056A publication Critical patent/JP2023541056A/ja
Publication of JP2023541056A5 publication Critical patent/JP2023541056A5/ja
Application granted granted Critical
Publication of JP7848190B2 publication Critical patent/JP7848190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023515802A 2020-09-14 2021-09-13 生体侵食性眼薬送達挿入物及び治療方法 Active JP7848190B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063078265P 2020-09-14 2020-09-14
US63/078,265 2020-09-14
US202163176430P 2021-04-19 2021-04-19
US63/176,430 2021-04-19
US202163190052P 2021-05-18 2021-05-18
US63/190,052 2021-05-18
PCT/US2021/050085 WO2022056392A1 (en) 2020-09-14 2021-09-13 Bioerodible ocular drug delivery insert and therapeutic method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026063649A Division JP2026129731A (ja) 2020-09-14 2026-04-08 生体侵食性眼薬送達挿入物及び治療方法

Publications (3)

Publication Number Publication Date
JP2023541056A JP2023541056A (ja) 2023-09-27
JP2023541056A5 JP2023541056A5 (enExample) 2024-09-26
JP7848190B2 true JP7848190B2 (ja) 2026-04-20

Family

ID=80629914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515802A Active JP7848190B2 (ja) 2020-09-14 2021-09-13 生体侵食性眼薬送達挿入物及び治療方法

Country Status (19)

Country Link
US (3) US12551368B2 (enExample)
EP (2) EP4696325A3 (enExample)
JP (1) JP7848190B2 (enExample)
KR (1) KR20230067641A (enExample)
CN (2) CN115531352B (enExample)
AU (1) AU2021340733A1 (enExample)
BR (1) BR112023004677A2 (enExample)
CA (1) CA3191463A1 (enExample)
DK (1) DK4210682T3 (enExample)
FI (1) FI4210682T3 (enExample)
HR (1) HRP20260727T1 (enExample)
IL (1) IL301227A (enExample)
LT (1) LT4210682T (enExample)
MX (1) MX2023002902A (enExample)
PT (1) PT4210682T (enExample)
RS (1) RS68167B1 (enExample)
SI (1) SI4210682T1 (enExample)
SM (1) SMT202600235T1 (enExample)
WO (1) WO2022056392A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067882A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
IL315331A (en) * 2022-03-11 2024-10-01 Eyepoint Pharmaceuticals Inc A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye
US20250186398A1 (en) * 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye
TW202345804A (zh) * 2022-03-11 2023-12-01 美商視點製藥有限公司 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
US20240024093A1 (en) 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
JP2025525881A (ja) * 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121568687A (zh) 2023-04-27 2026-02-24 艾博莱特克斯有限公司 包含聚乙烯醇的弹性体基质
KR102618788B1 (ko) * 2023-06-19 2023-12-28 국민대학교산학협력단 알티라티닙 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 안질환 예방 또는 치료용 약학 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018231811A1 (en) 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DK1592407T3 (da) * 2003-01-24 2010-04-19 Psivida Inc Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af carbonanhydraseinhibitorer
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20110238036A1 (en) 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
CA2848397C (en) * 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2013071264A1 (en) 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US20160317438A1 (en) 2015-04-29 2016-11-03 Psivida Us, Inc. Injectable sustained release intraocular device
AU2016361579B2 (en) 2015-11-25 2022-08-04 Incept, Llc Shape changing drug delivery devices and methods
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
SG11201901962QA (en) 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CN112165923B (zh) * 2018-04-19 2023-07-21 埃弗拉兹疗法有限公司 用于将物质注射到身体组织或器官的夹层中的装置
WO2020177678A1 (zh) * 2019-03-04 2020-09-10 江苏恒瑞医药股份有限公司 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
US20250186398A1 (en) * 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018231811A1 (en) 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JMMA Ophthalmology，2017年，Vol.135, No.7，pp.761-767
Journal of Ophthalmology，2017年，Article ID.6145651

Also Published As

Publication number Publication date
CN115243682A (zh) 2022-10-25
DK4210682T3 (da) 2026-06-08
US20260151260A1 (en) 2026-06-04
EP4210682B1 (en) 2026-03-25
PT4210682T (pt) 2026-05-27
RS68167B1 (sr) 2026-06-30
FI4210682T3 (fi) 2026-05-28
HRP20260727T1 (hr) 2026-07-31
AU2021340733A1 (en) 2023-05-18
JP2023541056A (ja) 2023-09-27
US20260191682A1 (en) 2026-07-09
CN115531352A (zh) 2022-12-30
EP4696325A3 (en) 2026-05-06
MX2023002902A (es) 2023-04-05
CN115531352B (zh) 2025-04-25
KR20230067641A (ko) 2023-05-16
US20220168142A1 (en) 2022-06-02
WO2022056392A1 (en) 2022-03-17
EP4696325A2 (en) 2026-02-18
SMT202600235T1 (it) 2026-07-16
IL301227A (en) 2023-05-01
SI4210682T1 (sl) 2026-07-31
AU2021340733A9 (en) 2024-04-18
BR112023004677A2 (pt) 2023-05-09
CA3191463A1 (en) 2022-03-17
US12551368B2 (en) 2026-02-17
LT4210682T (lt) 2026-06-10
EP4210682A1 (en) 2023-07-19
EP4210682A4 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
CN115531352B (zh) 可生物蚀解的眼部药物递送插入剂及治疗方法
KR20240156416A (ko) 눈의 병태 치료를 위한 지속적 투여 요법
CA2830555A1 (en) Intraocular drug delivery device and associated methods
KR20250002220A (ko) 안구 약물 전달 삽입물을 투여하여 연령 관련 황반 변성을 예방하는 방법
AU2017388230A1 (en) Intraocular drug delivery device and associated methods
TW202110445A (zh) 治療眼部疾病之組合物
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40118701A (en) Continuous dosing regimen for treatment of a condition of the eye
HK40118703A (en) Method of treating wet age-related macular degeneration
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method
US20250186336A1 (en) Method of treating wet age-related macular degeneration
HK40118700A (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260408

R150 Certificate of patent or registration of utility model

Ref document number: 7848190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150